Adverse events other than severe hypoglycaemic episodes (all non‐severe hypoglycaemic episodes) (Events per participant per month)
1 finding from 1 review
Socioeconomic effects
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Macrovascular complications
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Microvascular complications
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality ‐ not reported · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life and treatment satisfaction ‐ not reported · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HbA1c (glycated haemoglobin), change · patients with type 2 diabetes mellitus
1 finding from 1 review
Percentage of participants having at least one severe hypoglycaemic event · patients with type 2 diabetes mellitus
Insulin detemir (intervention) showed no clear difference in percentage of participants having at least one severe hypoglycaemic… compared with insulin glargin (control) (low certainty).
1 finding from 1 review
Percentage of participants having at least one hypoglycaemic event · patients with type 2 diabetes mellitus
Insulin detemir (intervention) showed no clear difference in percentage of participants having at least one hypoglycaemic event compared with insulin glargin (control) (low certainty).
1 finding from 1 review
Weight gain · patients with type 2 diabetes mellitus
1 finding from 1 review
Injection‐site reaction Rates of patients · patients with type 2 diabetes mellitus
Insulin detemir (intervention) may leads to higher percentage of participants having at least one injection site reaction compared with insulin glargin (control) (low certainty).
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe hypoglycaemia
It is very uncertain whether summary of findings: insulin detemir changes severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (very low certainty).
1 finding from 1 review
Non‐fatal myocardial infarction/stroke
1 finding from 1 review
Severe nocturnal hypoglycaemia (n/N) Definition: severe hypoglycaemia occurring 00:01‐05:59 (Davies 2014) or 23:00‐07:00 (BEGIN Young)
It is very uncertain whether summary of findings: insulin detemir changes severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (very low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
HbA1c (%)
1 finding from 1 review
Severe hypoglycaemia
Summary of findings: insulin detemir probably leads to lower severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with NPH insulin (moderate certainty).
1 finding from 1 review